Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA.
Blood (Impact Factor: 10.45). 07/2007; 110(2):695-708. DOI: 10.1182/blood-2006-11-051672
Source: PubMed


Recent evidence suggests that there is etiologic heterogeneity among the various subtypes of lymphoid neoplasms. However, epidemiologic analyses by disease subtype have proven challenging due to the numerous clinical and pathologic schemes used to classify lymphomas and lymphoid leukemias over the last several decades. On behalf of the International Lymphoma Epidemiology Consortium (InterLymph) Pathology Working Group, we present a proposed nested classification of lymphoid neoplasms to facilitate the analysis of lymphoid neoplasm subtypes in epidemiologic research. The proposed classification is based on the World Health Organization classification of lymphoid neoplasms and the International Classification of Diseases-Oncology, Third Edition (ICD-O-3). We also provide a translation into the proposed classification from previous classifications, including the Working Formulation, Revised European-American Lymphoma (REAL) classification, and ICD-O-2. We recommend that epidemiologic studies include analyses by lymphoma subtype to the most detailed extent allowable by sample size. The standardization of groupings for epidemiologic research of lymphoma subtypes is essential for comparing subtype-specific reports in the literature, harmonizing cases within a single study diagnosed using different systems, as well as combining data from multiple studies for the purpose of pooled analysis or meta-analysis, and will probably prove to be critical for elucidating etiologies of the various lymphoid neoplasms.

Download full-text


Available from: Christina A Clarke,
  • Source
    • "Our retrospective analysis encompassing 26 years has been additionally complicated by change in classification of PTCLs. The development of new diagnostic tools, such as anti-CD30 and ALK1 antibodies (The Non-Hodgkin's Lymphoma Classification Project, 1982; Stein et al, 1985; Harris et al, 1994; Pittaluga et al, 1997; Pulford et al, 1997; The Non-Hodgkin's Lymphoma Classification Project, 1997; Morton et al, 2007) as well as the more knowledgeable use and interpretation of molecular methods, i.e., clonality analyses , have improved the reliable diagnosis and subtyping of PTCL during recent years (Langerak et al, 2012). Therefore, all 69 cases were reviewed with current methods and reclassified according to the 2008 WHO classification (Swerdlow, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mature (peripheral) T-cell lymphoma (PTCL) other than anaplastic large cell lymphoma is a heterogeneous group of diseases and exceedingly rare in children and adolescents. Survival rates range between 46% and 85%. This study reports the disease characteristics, treatment and outcome of all patients with the diagnosis of mature TCL registered in the Berlin-Frankfurt-Munster non-Hodgkin lymphoma database between 1986 and 2012. All diagnoses were centrally reviewed and revised by clinico-pathological correlation according to the criteria of the current World Health Organization classification. Of the 69 patients originally registered as having PTCL, the diagnosis was confirmed in 38 of them. Most patients were treated with an anaplastic large cell lymphoma (ALCL)-like therapy regimen. Patients with PTCL-not otherwise specified comprised the largest group and showed a 5-year event-free survival rate of 61 ± 11%. Patients suffering from Natural Killer/T-cell- and hepatosplenic TCL had the poorest outcome. Our results suggest that the outcomes of children with mature TCL other than ALCL depend on the subtype and are worse than in all other paediatric lymphomas. The clinical experience presented in this largest study on paediatric mature TCL may serve as basis for future collaborative international prospective clinical trials.
    British Journal of Haematology 11/2014; 168(6). DOI:10.1111/bjh.13216 · 4.71 Impact Factor
  • Source
    • "The limitations of earlier pathological classifications on hematological disease hampered the study of the dose–risk relationship between alcohol drinking and different leukemia subtypes. Even if a recent classification by the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) [23] facilitated the analysis of lymphoid neoplasms in epidemiological research, the limited number of studies reporting data stratified for leukemia subtypes did not allow more precise conclusions. The latest revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia [42] recognized several molecularly defined subtypes of leukemia, and it also added some entities, defined principally by genetic features, only recently characterized. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The association between alcohol and leukemia risk has been addressed in several studies in the past two decades, but results have been inconsistent. Therefore, we conducted a systematic review and meta-analysis to quantify the dose–risk relation. Through the literature search up to August 2013, we identified 18 studies, 10 case-control and 8 cohorts, carried out in a total of 7142 leukemia cases. We derived pooled meta-analytic estimates using random-effects models, taking into account the correlation between estimates, and we performed a dose–risk analysis using a class of nonlinear random-effects meta-regression models. Stratified analyses were carried out on leukemia subtypes and groups, in order to identify possible etiologic differences. Compared with nondrinkers, the relative risks (RRs) for all leukemia were 0.94 [95% confidence interval (CI), 0.85–1.03], 0.90 (95% CI, 0.80–1.01) and 0.91 (95% CI, 0.81–1.02) for any, light (≤1 drink/day) and moderate to heavy (>1 drink/day) alcohol drinking, respectively. The summary RRs for any alcohol drinking were 1.47 (95% CI, 0.47–4.62) for acute lymphoblastic leukemia, 0.94 (95% CI 0.77–1.15) for chronic lymphocytic leukemia, 1.02 (95% CI, 0.86–1.21) for acute myeloid leukemia and 0.93 (95% CI 0.75–1.14) for chronic myeloid leukemia. The subgroup analysis on geographical area for all leukemia combined showed RRs of 0.84 (95% CI, 0.76–0.93), 0.92 (95% CI, 0.83–1.01) and 1.32 (95% CI, 1.02–1.70) for studies conducted in America, Europe and Asia, respectively. We did not find an increased risk of leukemia among alcohol drinkers. If any, a modest favorable effect emerged for light alcohol drinking, with a model-based risk reduction of approximately 10% in regular drinkers.
    Cancer Epidemiology 06/2014; 38(4):339-345. DOI:10.1016/j.canep.2014.06.001 · 2.71 Impact Factor
  • Source
    • ". WM is a very rare lymphoid malignancy, with an overall incidence estimated at 0.35 for WM and 0.63 for LPL/WM per 100,000 person-years during 2001–2003, representing 1.2% or 2.1% of all non-Hodgkin's lymphomas in the United States Surveillance Epidemiology and End Results (SEER) cancer registries, respectively [3]. Between 1996 and 2003, the crude incidence of LPL/WM was 0.078 per 100,000 person-years in Japan (0.112 for men and 0.048 for women) and 0.032 per 100,000 person-years in Taiwan (0.042 for men and 0.021 for women) [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Waldenström's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37-92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%, P = 0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73-111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.
    BioMed Research International 06/2014; 2014:253243. DOI:10.1155/2014/253243 · 1.58 Impact Factor
Show more